(Q71951276)

English

Distinct Changes in HIV Type 1 RNA versus p24 Antigen Levels in Serum during Short-Term Zidovudine Therapy in Asymptomatic Individuals with and without Progression to AIDS

scientific article published on 01 April 1995

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7632462%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7632462%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

Distinct Changes in HIV Type 1 RNA versus p24 Antigen Levels in Serum during Short-Term Zidovudine Therapy in Asymptomatic Individuals with and without Progression to AIDS (English)

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

1 reference

based on heuristic

inferred from title

author name string

S. Jurriaans

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7632462

24 June 2024

G. J. Weverling

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7632462

24 June 2024

J. Goudsmit

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7632462

24 June 2024

J. Boogaard

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7632462

24 June 2024

M. Brok

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7632462

24 June 2024

D. Van Strijp

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7632462

24 June 2024

J. Lange

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7632462

24 June 2024

M. Koot

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7632462

24 June 2024

B. Van Gemen

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7632462

24 June 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7632462

24 June 2024

publication date

1 April 1995

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7632462%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

full work available at URL

http://www.liebertpub.com/doi/pdf/10.1089/aid.1995.11.473

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

AIDS Research and Human Retroviruses

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7632462%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7632462%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7632462%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

473-479

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7632462%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

1

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase

2

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Inhibition of human immunodeficiency virus 1 reverse transcriptase by 3'-azidothymidine triphosphate

4

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Failure of zidovudine prophylaxis after accidental exposure to HIV-1.

5

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group

6

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

7

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex

8

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects

9

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group

10

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

11

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

12

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

13

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Preliminary analysis of the Concorde trial. Concorde Coordinating Committee

14

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Quantitation of human immunodeficiency virus type 1 in the blood of infected persons

16

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

17

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy

18

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

19

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

20

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

21

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017)

22

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

NASBATM isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection

23

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Detection of HIV-1 distribution in different blood fractions by two nucleic acid amplification assays

24

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection

25

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes

26

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay

27

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine

28

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Rapid and simple method for purification of nucleic acids

29

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus

30

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories

32

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?

33

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

34

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR

35

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction

36

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo.

37

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes

38

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment

39

1 reference

10.1089/AID.1995.11.473

https://api.crossref.org/works/10.1089/AID.1995.11.473

24 June 2024

Identifiers

10.1089/AID.1995.11.473

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7632462%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7632462%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q71951276&oldid=2187713367"